Quick Answer
Milestone Pharmaceuticals Inc. reported Total Assets of $113.56 million for the year ending 2025.
- Milestone Pharmaceuticals Inc. showed an increase of +50.4% in Total Assets from 2024 to 2025.
- This data is from Milestone Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on March 20, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $77.59 million | Q2 2019: $151.84 million | Q3 2019: $141.89 million | Q1 2020: $105.16 million | Q2 2020: $93.14 million | Q3 2020: $108.80 million | Q1 2021: $138.44 million | Q2 2021: $145.50 million | Q3 2021: $133.78 million | Q1 2022: $105.80 million | Q2 2022: $91.30 million | Q3 2022: $85.77 million | Q1 2023: $111.08 million | Q2 2023: $97.02 million | Q3 2023: $87.12 million | Q1 2024: $96.00 million | Q2 2024: $89.23 million | Q3 2024: $82.71 million | Q1 2025: $61.89 million | Q2 2025: $47.42 million | Q3 2025: $87.75 million.
- Over the full 8 years of available data (2018 to 2025), Milestone Pharmaceuticals Inc.'s Total Assets has grown by 28.9%.
- Historical annual values: Fiscal year 2025: $113.56 million | Fiscal year 2024: $75.50 million | Fiscal year 2023: $75.23 million | Fiscal year 2022: $74.48 million | Fiscal year 2021: $119.85 million | Fiscal year 2020: $149.97 million | Fiscal year 2019: $123.43 million | Fiscal year 2018: $88.08 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: